MX2020006015A - Composiciones y procedimientos para inhibir el agotamiento de celulas t. - Google Patents
Composiciones y procedimientos para inhibir el agotamiento de celulas t.Info
- Publication number
- MX2020006015A MX2020006015A MX2020006015A MX2020006015A MX2020006015A MX 2020006015 A MX2020006015 A MX 2020006015A MX 2020006015 A MX2020006015 A MX 2020006015A MX 2020006015 A MX2020006015 A MX 2020006015A MX 2020006015 A MX2020006015 A MX 2020006015A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- compositions
- methods
- inhibiting
- engineered
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones de células T y procedimientos de utilización de las mismas en el contexto de la terapia y el tratamiento. En particular, la invención proporciona células T que se modifican (por ejemplo, genética y/o funcionalmente) para mantener la funcionalidad bajo condiciones en las que las células T no modificadas muestran agotamiento. Las composiciones y procedimientos divulgados en la presente memoria encuentran uso para prevenir el agotamiento de células T modificadas por ingeniería (por ejemplo, receptor de antígeno quimérico (CAR)), así como de células T no modificadas, mejorando de esta manera la función de las células T (por ejemplo, actividad contra el cáncer o enfermedad infecciosa).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599299P | 2017-12-15 | 2017-12-15 | |
US201862738687P | 2018-09-28 | 2018-09-28 | |
PCT/US2018/065801 WO2019118902A2 (en) | 2017-12-15 | 2018-12-14 | Compositions and methods for inhibiting t cell exhaustion |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006015A true MX2020006015A (es) | 2020-10-12 |
Family
ID=66815349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006015A MX2020006015A (es) | 2017-12-15 | 2018-12-14 | Composiciones y procedimientos para inhibir el agotamiento de celulas t. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11400117B2 (es) |
EP (1) | EP3723774A4 (es) |
JP (1) | JP7505761B2 (es) |
KR (1) | KR20200100106A (es) |
CN (1) | CN111727045A (es) |
AU (1) | AU2018385706A1 (es) |
BR (1) | BR112020011893A2 (es) |
CA (1) | CA3084617A1 (es) |
IL (1) | IL275263A (es) |
MX (1) | MX2020006015A (es) |
SG (1) | SG11202005609PA (es) |
WO (1) | WO2019118902A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
EP4090432A4 (en) * | 2020-01-15 | 2024-04-17 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR ALTERING GAMMA DELTA T CELL ACTIVITY |
US20210309717A1 (en) | 2020-03-20 | 2021-10-07 | Lyell Immunopharma, Inc. | Novel Recombinant Cell Surface Markers |
CN111773380A (zh) * | 2020-04-26 | 2020-10-16 | 郑州大学第一附属医院 | Plpp1在制备t细胞免疫肿瘤相关药剂中的应用 |
TW202239768A (zh) | 2021-01-27 | 2022-10-16 | 美商萊爾免疫藥物股份有限公司 | 改良之免疫細胞療法 |
EP4281100A2 (en) * | 2021-01-27 | 2023-11-29 | The Trustees Of Dartmouth College | Immunostimulatory cytokine combination and therapeutic use thereof |
WO2022182891A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
WO2022182890A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
TW202246511A (zh) | 2021-02-25 | 2022-12-01 | 美商萊爾免疫藥物股份有限公司 | 靶向ny-eso-1之增強免疫細胞療法 |
WO2022256437A1 (en) | 2021-06-02 | 2022-12-08 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
WO2023010073A1 (en) * | 2021-07-28 | 2023-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for improving t cell persistence and function |
WO2023070041A1 (en) | 2021-10-21 | 2023-04-27 | Lyell Immunopharma, Inc. | Enhanced immune cell therapy |
IL312201A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing C-JUN |
WO2023077028A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Enhanced t cell therapy targeting ny-eso-1 |
AU2022376953A1 (en) | 2021-10-28 | 2024-05-02 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
WO2023164671A2 (en) * | 2022-02-25 | 2023-08-31 | Duke University | Compositions and methods for epigenome editing to enhance t cell therapy |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
WO2023225665A1 (en) | 2022-05-19 | 2023-11-23 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
WO2024020429A1 (en) | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
CN117844748A (zh) * | 2022-09-30 | 2024-04-09 | 北京昌平实验室 | 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法 |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958671A (en) * | 1996-04-23 | 1999-09-28 | Presidents And Fellows Of Harvard College | Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
JP2005536982A (ja) * | 2001-11-07 | 2005-12-08 | 麒麟麦酒株式会社 | インビトロにおけるt細胞増幅および増幅されたt細胞集団 |
WO2008095141A2 (en) * | 2007-01-31 | 2008-08-07 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
WO2013063019A1 (en) * | 2011-10-28 | 2013-05-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells |
AU2014368383B2 (en) * | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
EP3267969A1 (en) * | 2015-03-09 | 2018-01-17 | King's College London | Combination therapy with rar alpha agonists for enhancing th1 response |
EP3292200A4 (en) * | 2015-05-05 | 2018-10-31 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
US20210309965A1 (en) | 2016-03-21 | 2021-10-07 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
-
2018
- 2018-12-14 MX MX2020006015A patent/MX2020006015A/es unknown
- 2018-12-14 WO PCT/US2018/065801 patent/WO2019118902A2/en unknown
- 2018-12-14 JP JP2020551791A patent/JP7505761B2/ja active Active
- 2018-12-14 CN CN201880089475.9A patent/CN111727045A/zh active Pending
- 2018-12-14 SG SG11202005609PA patent/SG11202005609PA/en unknown
- 2018-12-14 KR KR1020207020043A patent/KR20200100106A/ko not_active Application Discontinuation
- 2018-12-14 EP EP18889872.0A patent/EP3723774A4/en active Pending
- 2018-12-14 BR BR112020011893-1A patent/BR112020011893A2/pt unknown
- 2018-12-14 US US16/221,155 patent/US11400117B2/en active Active
- 2018-12-14 CA CA3084617A patent/CA3084617A1/en active Pending
- 2018-12-14 AU AU2018385706A patent/AU2018385706A1/en active Pending
-
2020
- 2020-06-10 IL IL275263A patent/IL275263A/en unknown
-
2022
- 2022-06-27 US US17/850,825 patent/US20220401486A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020121965A (ru) | 2022-01-17 |
US11400117B2 (en) | 2022-08-02 |
SG11202005609PA (en) | 2020-07-29 |
US20190183932A1 (en) | 2019-06-20 |
EP3723774A2 (en) | 2020-10-21 |
CA3084617A1 (en) | 2019-06-20 |
KR20200100106A (ko) | 2020-08-25 |
BR112020011893A2 (pt) | 2020-11-24 |
WO2019118902A3 (en) | 2019-07-18 |
AU2018385706A1 (en) | 2020-06-25 |
JP7505761B2 (ja) | 2024-06-25 |
CN111727045A (zh) | 2020-09-29 |
EP3723774A4 (en) | 2021-09-08 |
WO2019118902A2 (en) | 2019-06-20 |
JP2021508489A (ja) | 2021-03-11 |
IL275263A (en) | 2020-07-30 |
US20220401486A1 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006015A (es) | Composiciones y procedimientos para inhibir el agotamiento de celulas t. | |
MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
MX2019012233A (es) | Anticuerpos anti-sirpa. | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
MX2019008413A (es) | Celulas pluripotentes inmunodiseñadas. | |
MX2019003886A (es) | Receptores de antigenos quimericos para el tratamiento del cancer. | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
MX2019001414A (es) | Angiogenesis utilizando celulas madre placentarias. | |
MX2012011543A (es) | Tratamiento de sarcoidosis empleando celulas madre placentarias. | |
NZ711946A (en) | Newcastle disease viruses and uses thereof | |
NZ631701A (en) | Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases | |
IN2014KN02933A (es) | ||
MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
MX2012010434A (es) | Compuestos y composiciones novedosas para atacar a las celulas madre del cancer. | |
SG10201901157QA (en) | Cancer diagnosis and therapy | |
TR201818825T4 (tr) | Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar | |
MX2022002682A (es) | Anticuerpos anti-cd73. | |
MX2014000567A (es) | Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios. | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. |